CSBR
Price
$6.95
Change
-$0.11 (-1.56%)
Updated
Sep 3 closing price
Capitalization
95.83M
6 days until earnings call
PHAT
Price
$11.88
Change
+$0.03 (+0.25%)
Updated
Sep 3 closing price
Capitalization
844.23M
63 days until earnings call
Interact to see
Advertisement

CSBR vs PHAT

Header iconCSBR vs PHAT Comparison
Open Charts CSBR vs PHATBanner chart's image
Champions Oncology
Price$6.95
Change-$0.11 (-1.56%)
Volume$8.09K
Capitalization95.83M
Phathom Pharmaceuticals
Price$11.88
Change+$0.03 (+0.25%)
Volume$1.82M
Capitalization844.23M
CSBR vs PHAT Comparison Chart in %
Loading...
CSBR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CSBR vs. PHAT commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CSBR is a StrongBuy and PHAT is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (CSBR: $7.06 vs. PHAT: $11.85)
Brand notoriety: CSBR and PHAT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CSBR: 29% vs. PHAT: 113%
Market capitalization -- CSBR: $95.83M vs. PHAT: $844.23M
CSBR [@Biotechnology] is valued at $95.83M. PHAT’s [@Biotechnology] market capitalization is $844.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CSBR’s FA Score shows that 1 FA rating(s) are green whilePHAT’s FA Score has 0 green FA rating(s).

  • CSBR’s FA Score: 1 green, 4 red.
  • PHAT’s FA Score: 0 green, 5 red.
According to our system of comparison, CSBR is a better buy in the long-term than PHAT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CSBR’s TA Score shows that 5 TA indicator(s) are bullish while PHAT’s TA Score has 5 bullish TA indicator(s).

  • CSBR’s TA Score: 5 bullish, 5 bearish.
  • PHAT’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, PHAT is a better buy in the short-term than CSBR.

Price Growth

CSBR (@Biotechnology) experienced а +4.90% price change this week, while PHAT (@Biotechnology) price change was -5.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +16.10%, and the average quarterly price growth was +32.67%.

Reported Earning Dates

CSBR is expected to report earnings on Sep 10, 2025.

PHAT is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHAT($844M) has a higher market cap than CSBR($95.8M). PHAT YTD gains are higher at: 45.936 vs. CSBR (-17.620). CSBR has higher annual earnings (EBITDA): 8.43M vs. PHAT (-256.76M). PHAT has more cash in the bank: 150M vs. CSBR (3.2M). CSBR has less debt than PHAT: CSBR (6.44M) vs PHAT (206M). PHAT has higher revenues than CSBR: PHAT (114M) vs CSBR (58.6M).
CSBRPHATCSBR / PHAT
Capitalization95.8M844M11%
EBITDA8.43M-256.76M-3%
Gain YTD-17.62045.936-38%
P/E Ratio21.06N/A-
Revenue58.6M114M51%
Total Cash3.2M150M2%
Total Debt6.44M206M3%
FUNDAMENTALS RATINGS
CSBR vs PHAT: Fundamental Ratings
CSBR
PHAT
OUTLOOK RATING
1..100
1680
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8100
PRICE GROWTH RATING
1..100
4935
P/E GROWTH RATING
1..100
47100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PHAT's Valuation (77) in the null industry is in the same range as CSBR (84) in the Biotechnology industry. This means that PHAT’s stock grew similarly to CSBR’s over the last 12 months.

PHAT's Profit vs Risk Rating (100) in the null industry is in the same range as CSBR (100) in the Biotechnology industry. This means that PHAT’s stock grew similarly to CSBR’s over the last 12 months.

CSBR's SMR Rating (8) in the Biotechnology industry is significantly better than the same rating for PHAT (100) in the null industry. This means that CSBR’s stock grew significantly faster than PHAT’s over the last 12 months.

PHAT's Price Growth Rating (35) in the null industry is in the same range as CSBR (49) in the Biotechnology industry. This means that PHAT’s stock grew similarly to CSBR’s over the last 12 months.

CSBR's P/E Growth Rating (47) in the Biotechnology industry is somewhat better than the same rating for PHAT (100) in the null industry. This means that CSBR’s stock grew somewhat faster than PHAT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CSBRPHAT
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 7 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 13 days ago
85%
Declines
ODDS (%)
Bearish Trend 8 days ago
78%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
CSBR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCIGX34.66N/A
N/A
Fidelity Advisor Small Cap Growth I
RYBCX63.05-0.18
-0.28%
Rydex Basic Materials C
CBBYX6.69-0.02
-0.30%
AB Relative Value Advisor
AFVLX23.09-0.17
-0.73%
Applied Finance Select Investor
SOIVX35.59-0.29
-0.81%
Spirit of America Large Cap Value Inst

CSBR and

Correlation & Price change

A.I.dvisor tells us that CSBR and LIXT have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CSBR and LIXT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CSBR
1D Price
Change %
CSBR100%
+3.82%
LIXT - CSBR
25%
Poorly correlated
-6.97%
CVAC - CSBR
24%
Poorly correlated
N/A
PYPD - CSBR
24%
Poorly correlated
+1.79%
PHAT - CSBR
23%
Poorly correlated
-2.71%
PMN - CSBR
23%
Poorly correlated
-0.61%
More

PHAT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHAT has been loosely correlated with KLTO. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAT jumps, then KLTO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAT
1D Price
Change %
PHAT100%
-2.71%
KLTO - PHAT
42%
Loosely correlated
-10.62%
RGNX - PHAT
35%
Loosely correlated
+2.13%
URGN - PHAT
34%
Loosely correlated
+0.41%
ACIU - PHAT
33%
Poorly correlated
+8.33%
PDSB - PHAT
32%
Poorly correlated
+0.81%
More